257 related articles for article (PubMed ID: 35235820)
1. New Drugs Approved in 2021.
Ebied AM; Elmariah H; Cooper-DeHoff RM
Am J Med; 2022 Jul; 135(7):836-839. PubMed ID: 35235820
[TBL] [Abstract][Full Text] [Related]
2. New Drugs Approved in 2022.
Ebied AM; Elmariah H; Cooper-DeHoff RM
Am J Med; 2023 Jun; 136(6):545-550. PubMed ID: 36889492
[TBL] [Abstract][Full Text] [Related]
3. New Drugs Approved in 2019.
Ebied AM; Patel KH; Cooper-DeHoff RM
Am J Med; 2020 Jun; 133(6):675-678. PubMed ID: 32145207
[TBL] [Abstract][Full Text] [Related]
4. New Drugs Approved in 2020.
Ebied AM; Elmariah H; Cooper-DeHoff RM
Am J Med; 2021 Sep; 134(9):1096-1100. PubMed ID: 33939997
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
6. New Drug Approvals in 2018 - Another Record Year!
Ebied AM; Na J; Cooper-DeHoff RM
Am J Med; 2019 Sep; 132(9):1038-1043. PubMed ID: 30853471
[TBL] [Abstract][Full Text] [Related]
7. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
Monge AN; Sigelman DW; Temple RJ; Chahal HS
JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
[TBL] [Abstract][Full Text] [Related]
8. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
9. 2017 Is Banner Year for Drug Approvals by the Food and Drug Administration.
Ebied AM; Cooper-DeHoff RM
Am J Med; 2018 Sep; 131(9):1025-1033. PubMed ID: 29626430
[TBL] [Abstract][Full Text] [Related]
10. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
11. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
12. Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
Demirci E; Omes-Smit G; Zwiers A
Clin Transl Sci; 2023 Jul; 16(7):1127-1133. PubMed ID: 37013379
[TBL] [Abstract][Full Text] [Related]
13. A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs.
Brown DG
J Med Chem; 2024 Feb; 67(3):1690-1700. PubMed ID: 38233132
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
15. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
16. 2021 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2022 Aug; 27(8):2057-2064. PubMed ID: 35439613
[TBL] [Abstract][Full Text] [Related]
17. Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022.
Seoane-Vazquez E; Rodriguez-Monguio R; Powers JH
Sci Rep; 2024 Feb; 14(1):3325. PubMed ID: 38336899
[TBL] [Abstract][Full Text] [Related]
18. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
Joppi R; Bertele V; Vannini T; Garattini S; Banzi R
Br J Clin Pharmacol; 2020 Jan; 86(1):170-174. PubMed ID: 31657044
[TBL] [Abstract][Full Text] [Related]
19. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
Beakes-Read G; Neisser M; Frey P; Guarducci M
Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
[TBL] [Abstract][Full Text] [Related]
20. Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.
Chambers JD; Thorat T; Wilkinson CL; Neumann PJ
Health Aff (Millwood); 2017 Aug; 36(8):1408-1415. PubMed ID: 28784733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
